News

Philogen's focus on research and development activities within the biotechnology sector across multiple regions has yielded positive results. The company's late‑stage assets and strategic partnerships could shift revenue from milestone payments to stable product sales, potentially mitigating future risks.

Full article

Philogen S.p.A., a biotechnology company operating in Italy, Switzerland, the United States, and the European Union, has demonstrated impressive financial performance and growth. The company's debt to equity ratio has plummeted from 10.3% to 0.01% over five years, showcasing financial discipline. Philogen reported net income of €229.68 million for...

Full article

The company's guidance for 2026 indicates a forecasted high single‑digit percentage decline in low molecular weight heparin sales, primarily due to market competition. Despite these challenges, ROVI is investing in vertical integration to remain competitive and expects the business to continue growing in the long term. The company's expansion into...

Full article

ROVI's financial position remains solid with a net debt of EUR14.9 million and plans to propose a dividend payout of 35 % of consolidated net profit. The company maintains its commitment to reaching EUR700 million in CDMO sales by 2030. However, there are concerns regarding the heparin division due to lower bemiparin sales driven by high inventory...

Full article

ROVI's Q1 2026 results show a decrease in operating revenues by 1.5 % compared to Q1 2025, totaling EUR152.5 million. However, gross profit increased by 5 % to EUR95 million, with a significant improvement in gross margin of 3.8 percentage points to 62.3 %. The contract manufacturing business (CDMO) revenue grew by 5 %, while Okedi sales surged by...

Full article

Simultaneously, Italy’s competition authority (AGCM) has launched an investigation into a mobile‑network‑sharing and 5G rollout agreement between Telecom Italia (TIT.MI) and Swisscom’s Fastweb unit. The probe, reported on Monday by Reuters, will conclude by an April 2027 deadline. The inquiry could influence Swisscom’s strategic trajectory and mark...

Full article

Swisscom AG’s market profile shows a cautious outlook: its Zacks Rank is #4 (Sell) and it earned an “F” in the Value category, reflecting a forward P/E of 26.50, a PEG of 2.06 and a P/B of 30.16. In contrast, Telefonica Brasil (VIV) holds a #2 (Buy) rank, a forward P/E of 17.24, a PEG of 0.97 and a P/B of 2.05, earning a Value grade of B. The valua...

Full article

Analysts highlight a shift in growth trajectory, with the company’s annualised revenue growth expected to accelerate to 6.1 % by year‑end 2026, aligning closely with the industry’s 6.3 % forecast. This positions Knorr‑Bremse to match peer growth rates.

Full article

Knorr‑Bremse AG (KBX) reported a quarterly miss: revenues fell 2.7 % and statutory EPS dipped 6.5 % below analyst expectations. Despite the shortfall, the consensus from 14 analysts now forecasts a 4.5 % revenue rise to €8.25 bn in 2026, with statutory EPS projected to climb 27 % to €4.34. The average price target remains €113, reflecting a stable...

Full article

With its early entry into voice‑based intoxication detection, MindBio seeks a first‑mover advantage in an emerging field. The dual‑channel strategy—consumer and enterprise—positions the company to commercialize its technology at both individual and industrial scales.

Full article